EGFR and neoplasm: In the present study, we assessed EGFR protein expression, gene amplification status and P-Akt protein expression, in tumours without EGFR tyrosine kinase point mutations, such as HGG, in order to understand why disease is controlled, sometimes for a long-lasting period, by gefitinib in a fraction of patients.